Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: MacroRisk Analytics/EconomicInvestor
Provider: Stock Traders Daily
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sagent Pharmaceuticals Inc issues FY 2014 guidance; Net income guidance below analysts' estimates

Tuesday, 11 Feb 2014 07:00am EST 

Sagent Pharmaceuticals Inc:Expects FY 2014 net revenue to be in the range of $250-$290 mln.Expects FY 2014 reported net income to be in the range of a $10 mln loss to $10 mln in earnings.FY 2014 revenue of $283 mln and net income of $16.07 mln - Thomson Reuters I/B/E/S. 

Company Quote

5 May 2015